1095823-39-4 Usage
General Description
5-Chloro-4-(trifluoromethyl)pyridin-2-amine is a chemical compound with the molecular formula C6H4ClF3N2. It is a derivative of pyridine and contains a chlorine atom, a trifluoromethyl group, and an amino group attached to the pyridine ring. 5-Chloro-4-(trifluoromethyl)pyridin-2-amine is used in the pharmaceutical industry as an intermediate in the synthesis of various pharmaceutical drugs and agrochemicals. It may also have potential applications in medicinal chemistry and drug discovery. 5-Chloro-4-(trifluoromethyl)pyridin-2-amine is a valuable building block for creating new molecules with potential biological activity and is of interest to researchers in the field of organic and medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 1095823-39-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,5,8,2 and 3 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1095823-39:
(9*1)+(8*0)+(7*9)+(6*5)+(5*8)+(4*2)+(3*3)+(2*3)+(1*9)=174
174 % 10 = 4
So 1095823-39-4 is a valid CAS Registry Number.
1095823-39-4Relevant articles and documents
COMPOUNDS FOR TREATMENT OF EYE DISORDERS
-
Page/Page column 77, (2021/01/23)
Compounds of formula I as defined herein, or pharmaceutically acceptable salts, solvates or derivatives thereof, are potent inhibitors of angiogenesis and accordingly are of use in the treatment and prevention of various angiogenesis-related disorders such as cancer.
HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
-
Page/Page column 86; 87; 88, (2010/08/04)
The present invention provides compounds of formula (I) useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf -mediated diseases.
COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
-
Page/Page column 78, (2009/03/07)
The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.
